Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Literature DB >> 21643892

Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Abstract

Results from seven studies of four subcutaneous IgG preparations in patients with primary immune deficiencies show that the incidence of infection is inversely related to the steady-state IgG level. Maintaining higher IgG levels may be beneficial, and no given level is necessarily adequate for all patients.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21643892 DOI： 10.1007/s10875-011-9546-2

Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317

18 in total

1. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Authors: Sylvain Thépot; Marion Malphettes; Anaëlle Gardeur; Lionel Galicier; Bouchra Asli; Lionel Karlin; Laurence Gérard; Richard Laumont; Marie-Laure Doize; Bertrand Arnulf; Claire Fieschi; Djaouïda Bengoufa; Eric Oksenhendler
Journal: J Clin Immunol Date: 2010-07 Impact factor: 8.317

2. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

Authors: Vincent R Bonagura; Robert Marchlewski; Amanda Cox; David W Rosenthal
Journal: J Allergy Clin Immunol Date: 2008-07 Impact factor: 10.793

Review 3. Subcutaneous administration of IgG.

Authors: Melvin Berger
Journal: Immunol Allergy Clin North Am Date: 2008-11 Impact factor: 3.479

4. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

Authors: Mary Lucas; Martin Lee; Jenny Lortan; Eduardo Lopez-Granados; Siraj Misbah; Helen Chapel
Journal: J Allergy Clin Immunol Date: 2010-05-14 Impact factor: 10.793

5. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.

Authors: Richard L Wasserman; Isaac Melamed; Lisa Kobrynski; Steven D Strausbaugh; Mark R Stein; Marlies Sharkhawy; Werner Engl; Heinz Leibl; Luba Sobolevsky; David Gelmont; Richard I Schiff; William J Grossman
Journal: J Clin Immunol Date: 2011-03-22 Impact factor: 8.317

6. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors: Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal: Clin Immunol Date: 2010-08-01 Impact factor: 3.969

7. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study.

Authors: Isabella Quinti; Annarosa Soresina; Andrea Guerra; Roberto Rondelli; Giuseppe Spadaro; Carlo Agostini; Cinzia Milito; Amelia Chiara Trombetta; Marcella Visentini; Helene Martini; Alessandro Plebani; Massimo Fiorilli
Journal: J Clin Immunol Date: 2011-03-02 Impact factor: 8.317

Review 8. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

Authors: Ann Gardulf
Journal: BioDrugs Date: 2007 Impact factor: 5.807

9. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Authors: John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange
Journal: J Clin Immunol Date: 2010-05-08 Impact factor: 8.317

Review 10. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy.

Authors: Malini V Bhole; Janet Burton; Helen M Chapel
Journal: Immunol Allergy Clin North Am Date: 2008-11 Impact factor: 3.479

14 in total

Review 1. Considerations for dosing immunoglobulin in obese patients.

Authors: J P Hodkinson
Journal: Clin Exp Immunol Date: 2017-04-17 Impact factor: 4.330

2. Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation.

Authors: S A Misbah
Journal: Clin Exp Immunol Date: 2014-12 Impact factor: 4.330

3. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors: Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal: J Clin Immunol Date: 2013-12-12 Impact factor: 8.317

Review 4. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors: Richard L Wasserman
Journal: J Clin Immunol Date: 2012-07-25 Impact factor: 8.317

5. Bioavailability of IgG administered by the subcutaneous route.

Authors: Melvin Berger; Stephen Jolles; Jordan S Orange; John W Sleasman
Journal: J Clin Immunol Date: 2013-03-01 Impact factor: 8.317

6. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Authors: Jennifer Heimall; Junliang Chen; Joseph A Church; Rhonda Griffin; Isaac Melamed; Gary I Kleiner
Journal: J Clin Immunol Date: 2016-06-25 Impact factor: 8.317